Novel first-row transition-metal phosphates: hydrothermal synthesis and crystal structures.
Sign Up to like & getrecommendations! Published in 2022 at "Acta crystallographica. Section C, Structural chemistry"
DOI: 10.1107/s2053229622003692
Abstract: Two new compounds, sodium copper nickel diorthophosphate, Na2CuNi(PO4)2 (I), and dimanganese copper diorthophosphate, Mn2Cu(PO4)2 (II), were synthesized hydrothermally, yielding single crystals, and were studied by X-ray diffraction. In the crystal structures, various transition metals of… read more here.
Keywords: first row; crystal structures; po4; novel first ... See more keywords
Abstract 694: TK-216: a novel, first-in-class, small molecule inhibitor of EWS-FLI1 in early clinical development, for the treatment of Ewing Sarcoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-694
Abstract: One of the most significant challenges in creating more potent, less toxic treatments for patients is to identify new cancer therapeutic targets that distinguish the malignant from normal cells. EWS-FLI1 is a well-established Ewing sarcoma… read more here.
Keywords: ews fli1; 216 novel; novel first; ewing sarcoma ... See more keywords
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2019001079
Abstract: CD27, a costimulatory molecule on T cells, induces intracellular signals mediating cellular activation, proliferation, effector function, and cell survival on binding to its ligand, CD70. Varlilumab, a novel, first-in-class, agonist immunoglobulin G1 anti-CD27 antibody, mediates… read more here.
Keywords: cd27; hematologic malignancies; novel first; varlilumab novel ... See more keywords